Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia
- Conditions
- Mesenchymal Stem CellsThrombocytopenia
- Interventions
- Other: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2025-03-25
- Target Recruit Count
- 18
- Registration Number
- NCT04014166
- Locations
- 🇨🇳
Yunfei Chen, Tianjin, Tianjin, China
a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
- Conditions
- Multiple MyelomaPlasma Cell LeukemiaExtramedullary PlasmacytomaLoss of Chromosome 17pt(14;16)t(4;14)T(14;20)1Q21 AmplificationComplex Karyotype
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2Drug: PI+IMids+Dexamethasone as Consolidated Chemotherapy
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2019-07-05
- Target Recruit Count
- 50
- Registration Number
- NCT04008888
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies
- Conditions
- Relapsed and Refractory Hematological Malignancies
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia Patients
- Conditions
- ThrombocytopeniaSplenectomy
- Interventions
- Procedure: splenectomy
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2025-02-24
- Target Recruit Count
- 50
- Registration Number
- NCT03998059
- Locations
- 🇨🇳
Yunfei Chen, Tianjin, Tianjin, China
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2019-06-10
- Target Recruit Count
- 50
- Registration Number
- NCT03980002
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
- Conditions
- Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaTransformed Lymphoma
- Interventions
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2022-01-26
- Target Recruit Count
- 118
- Registration Number
- NCT03837873
- Locations
- 🇨🇳
the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳the First Affiliated Hospital of Jilin University, Changchun, Jilin, China
to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection
- Conditions
- Chronic HBV InfectionThrombocytopenia Purpura
- Interventions
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2023-08-14
- Target Recruit Count
- 48
- Registration Number
- NCT03664518
- Locations
- 🇨🇳
Ethics Committee of Blood disease hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
- Locations
- 🇨🇳
HBDH, Tianjin, Tianjin, China
The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2022-08-03
- Target Recruit Count
- 132
- Registration Number
- NCT03173612
- Locations
- 🇨🇳
InstituteHBDH, Tianjin, Tianjin, China
Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia, Pediatric
- Interventions
- Other: Risk-stratified therapy
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2017-05-30
- Target Recruit Count
- 320
- Registration Number
- NCT03165851
- Locations
- 🇨🇳
InstituteHBDH, Tianjin, Tianjin, China